Your browser doesn't support javascript.
loading
Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
Anwari, Palwasha; Burnett, Eleanor; Chavers, Tyler P; Samsor, Akmal; Safi, Helah; Safi, Najibullah; Clark, Andrew D; Parashar, Umesh D; Tate, Jacqueline E.
Affiliation
  • Anwari P; London School of Hygiene and Tropical Medicine, London, United Kingdom. Electronic address: palwasha.anwari@lshtm.ac.uk.
  • Burnett E; Division of Viral Diseases, NCIRD, CDC, Atlanta, United States of America.
  • Chavers TP; Division of Viral Diseases, NCIRD, CDC, Atlanta, United States of America.
  • Samsor A; JS Consultancy, Kabul, Afghanistan.
  • Safi H; JS Consultancy, Kabul, Afghanistan.
  • Safi N; JS Consultancy, Kabul, Afghanistan.
  • Clark AD; London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Parashar UD; Division of Viral Diseases, NCIRD, CDC, Atlanta, United States of America.
  • Tate JE; Division of Viral Diseases, NCIRD, CDC, Atlanta, United States of America.
Vaccine ; 42(8): 2059-2064, 2024 Mar 19.
Article in En | MEDLINE | ID: mdl-38413278
ABSTRACT

BACKGROUND:

In January 2018, Afghanistan introduced the monovalent oral rotavirus vaccine (Rotarix) nationwide, administered as a 2-dose series at six and ten weeks of age. We describe characteristics of intussusception cases and assess potential intussusception risk associated with Rotarix vaccination in Afghan infants.

METHODS:

Multi-center prospective active hospital-based surveillance for intussusception was conducted from May 2018 to March 2022 in four sentinel sites in Afghanistan. We applied the Brighton Level 1 criteria for intussusception and verified vaccination status by reviewing vaccine cards. We used the self-controlled case series (SCCS) methodology to compare intussusception incidence in the 1 to 21 days after each dose of Rotarix vaccination against non-risk periods.

RESULTS:

A total of 468 intussusception cases were identified in infants under 12 months, with 264 cases aged between 28 and 245 days having confirmed vaccination status contributing to the SCCS analysis. Most case-patients (98 %) required surgery for treatment, and over half (59 %) of those who underwent surgery required intestinal resection. Nineteen (7 %) case-patients died. Eighty-six percent of case-patients received the first dose of Rotarix, and 69 % received the second dose before intussusception symptom onset. There was no increased risk of intussusception in the 1-7 days (relative incidence 0.9, 95 % CI 0.1, 7.5), 8-21 days (1.3, 95 % CI 0.4, 4.2), or 1-21 days (1.1, 95 % CI 0.4, 3.4) following receipt of the first dose or in the 1-7 days (0.2, 95 % CI 0.3, 1.8), 8-21 days (0.7, 95 % CI 0.3, 1.5), or 1-21 days (0.6, 95 % CI 0.3, 1.2) following the second dose.

CONCLUSION:

Rotarix vaccination was not associated with an increased intussusception risk, supporting its continued use in Afghanistan's immunization program. However, there was a high level of death and resection due to intussusception among Afghan infants.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rotavirus Infections / Rotavirus Vaccines / Intussusception Limits: Humans / Infant Country/Region as subject: Asia Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rotavirus Infections / Rotavirus Vaccines / Intussusception Limits: Humans / Infant Country/Region as subject: Asia Language: En Journal: Vaccine Year: 2024 Document type: Article Country of publication: Países Bajos